Cargando…

Acute Promyelocytic Leukemia: A Summary

Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all-trans retinoic acid and arsenic trioxide, which ha...

Descripción completa

Detalles Bibliográficos
Autor principal: Ryan, Meaghan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303006/
https://www.ncbi.nlm.nih.gov/pubmed/30588352
_version_ 1783382095736864768
author Ryan, Meaghan M.
author_facet Ryan, Meaghan M.
author_sort Ryan, Meaghan M.
collection PubMed
description Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all-trans retinoic acid and arsenic trioxide, which have improved remission and survival rates. Induction, consolidation, and maintenance regimens have now been studied and are outlined. As patients affected can develop severe bleeding complications, rapid diagnosis and initiation of appropriate treatment are vital. During treatment, unique complications such as disseminated intravascular coagulation and differentiation syndrome can occur. Prompt recognition of complications is imperative.
format Online
Article
Text
id pubmed-6303006
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-63030062018-12-26 Acute Promyelocytic Leukemia: A Summary Ryan, Meaghan M. J Adv Pract Oncol Review Article Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all-trans retinoic acid and arsenic trioxide, which have improved remission and survival rates. Induction, consolidation, and maintenance regimens have now been studied and are outlined. As patients affected can develop severe bleeding complications, rapid diagnosis and initiation of appropriate treatment are vital. During treatment, unique complications such as disseminated intravascular coagulation and differentiation syndrome can occur. Prompt recognition of complications is imperative. Harborside Press 2018-03 2018-03-01 /pmc/articles/PMC6303006/ /pubmed/30588352 Text en Copyright © 2018, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Ryan, Meaghan M.
Acute Promyelocytic Leukemia: A Summary
title Acute Promyelocytic Leukemia: A Summary
title_full Acute Promyelocytic Leukemia: A Summary
title_fullStr Acute Promyelocytic Leukemia: A Summary
title_full_unstemmed Acute Promyelocytic Leukemia: A Summary
title_short Acute Promyelocytic Leukemia: A Summary
title_sort acute promyelocytic leukemia: a summary
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303006/
https://www.ncbi.nlm.nih.gov/pubmed/30588352
work_keys_str_mv AT ryanmeaghanm acutepromyelocyticleukemiaasummary